Nucleosides for the treatment of respiratory RNA virus infections

Antiviral Chemistry and Chemotherapy

Volumn 26, Issue , 2018, Pages

  Jordan, Paul C ^a   Stevens, Sarah K ^a   Deval, Jerome ^a  

^a JOHNSON AND JOHNSON   (United States)

Author keywords

antiviral; coronavirus; influenza; nucleoside analog; picornavirus; Respiratory syncytial virus; rhinovirus; RNA dependent RNA polymerase

Indexed keywords

7 DEAZA 2' C METHYLADENOSINE; ANTIVIRUS AGENT; FAVIPIRAVIR; GENOMIC RNA; LUMICITABINE; MK 0608; NITD 008; NUCLEOSIDE ANALOG; OSELTAMIVIR; PALIVIZUMAB; PERAMIVIR; REMDESIVIR; RIBAVIRIN; RNA POLYMERASE; UNCLASSIFIED DRUG; ZANAMIVIR; NUCLEOSIDE;

ANTIVIRAL RESISTANCE; ARTICLE; CAUSAL ATTRIBUTION; CORONAVIRIDAE; CORONAVIRIDAE INFECTION; DRUG APPROVAL; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; EBOLA HEMORRHAGIC FEVER; EBOLAVIRUS; HUMAN; HUMAN RHINOVIRUS; INFLUENZA; NONHUMAN; ORTHOMYXOVIRIDAE; PARAMYXOVIRIDAE; PNEUMOVIRINAE; PREVALENCE; PRIORITY JOURNAL; RESPIRATORY VIRUS; RNA VIRUS INFECTION; STRUCTURE ACTIVITY RELATION; TREATMENT PLANNING; VIRAL RESPIRATORY TRACT INFECTION; VIRUS CAPSID; VIRUS INFECTIVITY; VIRUS REPLICATION; CHEMICAL STRUCTURE; CHEMISTRY; MICROBIAL SENSITIVITY TEST; MOLECULAR MODEL; RESPIRATORY TRACT INFECTION; RNA VIRUS; VIROLOGY;

ANTIVIRAL AGENTS; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; NUCLEOSIDES; RESPIRATORY TRACT INFECTIONS; RNA VIRUS INFECTIONS; RNA VIRUSES;

EID: 85051395653     PISSN: None     EISSN: 20402066     Source Type: Journal    
DOI: 10.1177/2040206618764483     Document Type: Article

References (170)

1. Ferkol T, andSchraufnagel D., The global burden of respiratory disease. Ann Am Thorac Soc 2014; 11: 404–40-6.
2. Gelderblom HR., Structure and classification of viruses. In: Baron S, (ed) Medical microbiology. 4th ed. Galveston: University of Texas Medical Branch, 1996.
3. Mackie PL., The classification of viruses infecting the respiratory tract. Paediatr Respir Rev 2003; 4: 84–90.
4. Kawaguchi A, Bates A, Lee BE. Virus detection in critically ill children with acute respiratory disease: a new profile in view of new technology. Acta Paediatr 2017; 107: 504–510.
5. Te Velthuis AJ, andFodor E., Influenza virus RNA polymerase: insights into the mechanisms of viral RNA synthesis. Nat Rev Microbiol 2016; 14: 479–493.
6. Muchmore EA, andVarki A., Selective inactivation of influenza C esterase: a probe for detecting 9-O-acetylated sialic acids. Science 1987; 236: 1293–129-5.
7. Song H, Qi J, Khedri Z. An open receptor-binding cavity of hemagglutinin-esterase-fusion glycoprotein from newly-identified influenza D virus: Basis for its broad cell tropism. PLOS Pathog 2016; 12: e1005411.
8. Rello J, andPop-Vicas A., Clinical review: Primary influenza viral pneumonia. Crit Care 2009; 13: 235.
9. Moghadami M., A narrative review of influenza: A seasonal and pandemic disease. Iran J Med Sci 2017; 42: 2–13.
10. Fowlkes A, Steffens A, Temte J. Incidence of medically attended influenza during pandemic and post-pandemic seasons through the Influenza Incidence Surveillance Project, 2009-2013. Lancet Respir Med 2015; 3: 709–718.
11. Girard MP, Cherian T, Pervikov Y. A review of vaccine research and development: Human acute respiratory infections. Vaccine 2005; 23: 5708–57-24.
12. Afonso CL, Amarasinghe GK, Banyai K. Taxonomy of the order Mononegavirales: update 2016. Arch Virol 2016; 161: 2351–23-60.
13. Hall CB., Respiratory syncytial virus and parainfluenza virus. New Engl J Med 2001; 344: 1917–19-28.
14. Marx A, Török TJ, Holma RC. Pediatric hospitalizations for croup (laryngotracheobronchitis): Biennial increases associated with human parainfluenza virus 1 epidemics. J Infect Dis 1997; 176: 1423–142-7.
15. Friesner RA, Banks JL, Murphy RB. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem 2004; 47: 1739–17-49.
16. Liu W-K, Liu Q, Chen D-H. Epidemiology and clinical presentation of the four human parainfluenza virus types. BMC Infect Dis 2013; 13: 28.
17. Iwane MK, Edwards KM, Szilagyi PG. Population-based surveillance for hospitalizations associated with respiratory syncytial virus, influenza virus, and parainfluenza viruses among young children. Pediatrics 2004; 113: 1758–17-64.
18. Nair H, Nokes DJ, Gessner BD. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010; 375: 1545–15-55.
19. Broadbent L, Groves H, Shields MD. Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials. Influenza Other Respir Virus 2015; 9: 169–1-78.
20. McNamara PS, andSmyth RL., The pathogenesis of respiratory syncytial virus disease in childhood. Br Med Bull 2002; 61: 13–28.
21. Krilov LR., Respiratory syncytial virus disease: update on treatment and prevention. Expert Rev Anti-infect Ther 2011; 9: 27–32.
22. Falsey AR., Human metapneumovirus infection in adults. Pediatr Infect Dis J 2008; 27: S80–S8-3.
23. Hamelin M-È, Abed Y, andBoivin G., Human metapneumovirus: A new player among respiratory viruses. Clin Infect Dis 2004; 38: 983–9-90.
24. Maggi F, Pifferi M, Vatteroni M. Human metapneumovirus associated with respiratory tract infections in a 3-year study of nasal swabs from infants in Italy. J Clin Microbiol 2003; 41: 2987–29-91.
25. Turner RB., Epidemiology, pathogenesis, and treatment of the common cold. Ann Allergy Asthma Immunol 1997; 78: 531–539; quiz 9–40.
26. Tapparel C, Siegrist F, Petty TJ. Picornavirus and enterovirus diversity with associated human diseases. Infect Genet Evol 2013; 14: 282–2-93.
27. Pappas DE, Hendley JO, Hayden FG. Symptom profile of common colds in school-aged children. Pediatr Infect Dis J 2008; 27: 8–11.
28. de Crom SCM, Rossen JWA, van Furth AM and Obihara CC. Enterovirus and parechovirus infection in children: a brief overview. European Journal of Pediatrics 2016; 175: 1023–1029.
29. Smura T, Blomqvist S, Vuorinen T. Recombination in the evolution of enterovirus C species sub-group that contains types CVA-21, CVA-24, EV-C95, EV-C96 and EV-C99. PloS One 2014; 9: e94579.
30. Royston L, andTapparel C., Rhinoviruses and respiratory enteroviruses: Not as simple as ABC. Viruses 2016; 8: 1–23.
31. Yi E-J, Shin Y-J, Kim J-H. Enterovirus 71 infection and vaccines. Clin Exp Vaccine Res 2017; 6: 4–14.
32. Lee KY., Enterovirus 71 infection and neurological complications. Korean J Pediatr 2016; 59: 395–401.
33. Lim XY, Ng LY, Tam PJ. Human coronaviruses: A review of virus–host interactions. Diseases 2016; 4: 1–28.
34. Pene F, Merlat A, Vabret A. Coronavirus 229E-related pneumonia in immunocompromised patients. Clin Infect Dis 2003; 37: 929–9-32.
35. Abdul-Rasool S, andFielding BC., Understanding human coronavirus HCoV-NL63. Open Virol J 2010; 4: 76–84.
36. Esper F, Weibel C, Ferguson D. Coronavirus HKU1 Infection in the United States. Emerg Infect Dis 2006; 12: 775–77-9.
37. Zhao Z, Zhang F, Xu M. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol 2003; 52: 715–7-20.
38. Cheng VC, Lau SK, Woo PC. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 2007; 20: 660–6-94.
39. Hijawi B, Abdallat M, Sayaydeh A. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East Mediterr Health J 2013; 19 Suppl 1: S12–S18.
40. Zumla A, Hui DS, andPerlman S., Middle east respiratory syndrome. Lancet (London, England) 2015; 386: 995–1007.
41. Zumla A, Chan JFW, Azhar EI. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov 2016; 15: 327–3-47.
42. Alsolamy S, andArabi YM., Infection with Middle East respiratory syndrome coronavirus. Canad J Respir Ther 2015; 51: 102.
43. Deval J., Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides. Drugs 2009; 69: 151–1-66.
44. Medina RA, andGarcía-Sastre A., Influenza A viruses: new research developments. Nat Rev Micro 2011; 9: 590–603.
45. Fodor E., The RNA polymerase of influenza a virus: mechanisms of viral transcription and replication. Acta Virol 2013; 57: 113–1-22.
46. Reich S, Guilligay D, Pflug A. Structural insight into cap-snatching and RNA synthesis by influenza polymerase. Nature 2014; 516: 361–36-6.
47. Ulmanen I, Broni BA, andKrug RM., Role of two of the influenza virus core P proteins in recognizing cap 1 structures (m7GpppNm) on RNAs and in initiating viral RNA transcription. Proc Natl Acad Sci 1981; 78: 7355–735-9.
48. Blass D, Patzelt E, andKuechler E., Identification of the cap binding protein of influenza virus. Nucl Acids Res 1982; 10: 4803–48-12.
49. Guilligay D, Tarendeau F, Resa-Infante P. The structural basis for cap binding by influenza virus polymerase subunit PB2. Nat Struct Mol Biol 2008; 15: 500–50-6.
50. Dias A, Bouvier D, Crepin T. The cap-snatching endonuclease of influenza virus polymerase resides in the PA subunit. Nature 2009; 458: 914–91-8.
51. N reveals an endonuclease active site. Nature 2009; 458: 909.
52. Pflug A, Guilligay D, Reich S. Structure of influenza A polymerase bound to the viral RNA promoter. Nature 2014; 516: 355–3-60.
53. Kirui J, Bucci MD, Poole DS. Conserved features of the PB2 627 domain impact influenza virus polymerase function and replication. J Virol 2014; 88: 5977–59-86.
54. Nilsson BE, te Velthuis AJW, andFodor E., Role of the PB2 627 domain in influenza A virus polymerase function. J Virol 2017; 91: e02467–16.
55. te Velthuis AJW, Robb NC, Kapanidis AN. The role of the priming loop in influenza A virus RNA synthesis. Nat Microbiol 2016; 1: 16029.
56. Stevaert A, andNaesens L., The influenza virus polymerase complex: An update on its structure, functions, and significance for antiviral drug design. Med Res Rev 2016; 36: 1127–11-73.
57. Noton SL, andFearns R., Initiation and regulation of paramyxovirus transcription and replication. Virology 2015; 479–480: 545–554.
58. Fearns R, andPlemper RK., Polymerases of paramyxoviruses and pneumoviruses. Virus Res 2017; 234: 87–102.
59. Fearns R, andDeval J., New antiviral approaches for respiratory syncytial virus and other mononegaviruses: Inhibiting the RNA polymerase. Antiviral Res 2016; 134: 63–76.
60. Collins PL, Hill MG, Cristina J. Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus. Proc Natl Acad Sci 1996; 93: 81–8-5.
61. Collins PL, Hill MG, Camargo E. Production of infectious human respiratory syncytial virus from cloned cDNA confirms an essential role for the transcription elongation factor from the 5' proximal open reading frame of the M2 mRNA in gene expression and provides a capability for vaccine development. Proc Natl Acad Sci 1995; 92: 11563–1156-7.
62. Mazumder B, Adhikary G, andBarik S., Bacterial expression of human respiratory syncytial viral phosphoprotein P and identification of Ser237 as the site of phosphorylation by cellular casein kinase II. Virology 1994; 205: 93–103.
63. Pereira N, Cardone C, Lassoued S. New insights into structural disorder in human respiratory syncytial virus phosphoprotein and implications for binding of protein partners. J Biol Chem 2017; 292: 2120–21-31.
64. Mason SW, Aberg E, Lawetz C. Interaction between human respiratory syncytial virus (RSV) M2-1 and P proteins is required for reconstitution of M2-1-dependent RSV minigenome activity. J Virol 2003; 77: 10670–1067-6.
65. Blondot M-L, Dubosclard V, Fix J. Structure and functional analysis of the RNA-and viral phosphoprotein-binding domain of respiratory syncytial virus M2-1 protein. PLoS Pathog 2012; 8: e1002734.
66. Galloux M, Tarus B, Blazevic I. Characterization of a viral phosphoprotein binding site on the surface of the respiratory syncytial nucleoprotein. J Virol 2012; 86: 8375–83-87.
67. Ghildyal R, Ho A, andJans DA., Central role of the respiratory syncytial virus matrix protein in infection. FEMS Microbiol Rev 2006; 30: 692–705.
68. Liang B, Li Z, Jenni S. Structure of the L protein of vesicular stomatitis virus from electron cryomicroscopy. Cell 2015; 162: 314–3-27.
69. Poch O, Blumberg BM, Bougueleret L. Sequence comparison of five polymerases (L proteins) of unsegmented negative-strand RNA viruses: theoretical assignment of functional domains. J Gen Virol 1990; 71: 1153–11-62.
70. Rahmeh AA, Schenk AD, Danek EI. Molecular architecture of the vesicular stomatitis virus RNA polymerase. Proc Natl Acad Sci USA 2010; 107: 20075–200-80.
71. Kallberg M, Wang H, Wang S. Template-based protein structure modeling using the RaptorX web server. Nat Protoc 2012; 7: 1511–15-22.
72. Paesen GC, Collet A, Sallamand C, et al. X-ray structure and activities of an essential mononegavirales L-protein domain. Nat Commun 2015; 6: 8749.
73. Li J, Rahmeh A, Morelli M. A conserved motif in region v of the large polymerase proteins of nonsegmented negative-sense RNA viruses that is essential for mRNA capping. J Virol 2008; 82: 775–7-84.
74. Bujnicki JM, andRychlewski L., In silico identification, structure prediction and phylogenetic analysis of the 2′-O-ribose (cap 1) methyltransferase domain in the large structural protein of ssRNA negative-strand viruses. Prot Eng Des Select 2002; 15: 101–10-8.
75. Ogino T, andBanerjee AK., Unconventional mechanism of mRNA capping by the RNA-dependent RNA polymerase of vesicular stomatitis virus. Mol Cell 2007; 25: 85–97.
76. Ogino T., In vitro capping and transcription of rhabdoviruses. Methods 2013; 59: 188–1-98.
77. Decroly E, Ferron F, Lescar J. Conventional and unconventional mechanisms for capping viral mRNA. Nat Rev Micro 2012; 10: 51–65.
78. Ferrer-Orta C, Ferrero D, andVerdaguer N., RNA-dependent RNA polymerases of picornaviruses: from the structure to regulatory mechanisms. Viruses 2015; 7: 4438–44-60.
79. van Dijk AA, Makeyev EV, andBamford DH., Initiation of viral RNA-dependent RNA polymerization. J Gen Virol 2004; 85: 1077–10-93.
80. Ferrer-Orta C, Arias A, Escarmís C. A comparison of viral RNA-dependent RNA polymerases. Curr Opin Struct Biol 2006; 16: 27–34.
81. Paul AV., Possible unifying mechanism of picornavirus genome replication. In: Semler BL, andWimmer E, (eds) Molecular biology of picornavirus. Washington, DC: ASM Press, 2002, pp.227–2-46.
82. Peersen OB., Picornaviral polymerase structure, function, and fidelity modulation. Virus Res 2017; 234: 4–20.
83. Paul AV, Peters J, Mugavero J. Biochemical and genetic studies of the VPg uridylylation reaction catalyzed by the RNA polymerase of poliovirus. J Virol 2003; 77: 891–904.
84. Paul AV, Yin J, Mugavero J. A “slide-back” mechanism for the initiation of protein-primed RNA synthesis by the RNA polymerase of poliovirus. J Biol Chem 2003; 278: 43951–439-60.
85. Rieder E, Paul AV, Kim DW. Genetic and biochemical studies of polioviruscis-acting replication element cre in relation to VPg uridylylation. J Virol 2000; 74: 10371–103-80.
86. Appleby TC, Luecke H, Shim JH. Crystal structure of complete rhinovirus RNA polymerase suggests front loading of protein primer. J Virol 2005; 79: 277–2-88.
87. Chen C, Wang Y, Shan C. Crystal structure of enterovirus 71 RNA-dependent RNA polymerase complexed with its protein primer VPg: implication for a trans mechanism of VPg uridylylation. J Virol 2013; 87: 5755–57-68.
88. Gong P, andPeersen OB., Structural basis for active site closure by the poliovirus RNA-dependent RNA polymerase. Proc Natl Acad Sci 2010; 107: 22505–225-10.
89. Černý J, Bolfíková BČ, Valdes JJ. Evolution of tertiary structure of viral RNA dependent polymerases. PloS One 2014; 9: e96070.
90. Hansen JL, Long AM, andSchultz SC., Structure of the RNA-dependent RNA polymerase of poliovirus. Structure 1997; 5: 1109–11 22.
91. Poch O, Sauvaget I, Delarue M. Identification of four conserved motifs among the RNA-dependent polymerase encoding elements. EMBO J 1989; 8: 3867–3874.
92. Thompson AA, andPeersen OB., Structural basis for proteolysis‐dependent activation of the poliovirus RNA‐dependent RNA polymerase. EMBO J 2004; 23: 3462–34-71.
93. Gohara DW, Crotty S, Arnold JJ. Poliovirus RNA-dependent RNA polymerase (3Dpol): Structural, biochemical, and biological analysis of conserved structural motifs A and B. J Biol Chem 2000; 275: 25523–25532.
94. Lyle JM, Bullitt E, Bienz K. Visualization and functional analysis of RNA-dependent RNA polymerase lattices. Science 2002; 296: 2218–22-22.
95. Wang J, Lyle JM, andBullitt E., Surface for catalysis by poliovirus RNA-dependent RNA polymerase. J Mol Biol 2013; 425: 2529–25-40.
96. Hobson SD, Rosenblum ES, Richards OC. Oligomeric structures of poliovirus polymerase are important for function. EMBO J 2001; 20: 1153–11-63.
97. Pathak HB, Ghosh SKB, Roberts AW. Structure-function relationships of the RNA-dependent RNA polymerase from poliovirus (3Dpol) A surface of the primary oligomerization domain functions in capsid precursor processing and VPg uridylylation. J Biol Chem 2002; 277: 31551–315-62.
98. Posthuma CC, te Velthuis AJW, andSnijder EJ., Nidovirus RNA polymerases: Complex enzymes handling exceptional RNA genomes. Virus Res 2017; 234: 58–73.
99. Perlman S, andNetland J., Coronaviruses post-SARS: Update on replication and pathogenesis. Nat Rev Microbiol 2009; 7: 439–4-50.
100. Subissi L, Posthuma CC, Collet A. One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities. Proc Natl Acad Sci 2014; 111: E3900–E3909.
101. Lehmann KC, Gulyaeva A, Zevenhoven-Dobbe JC. Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses. Nucl Acids Res 2015; 43: 8416–84-34.
102. Xu X, Liu Y, Weiss S. Molecular model of SARS coronavirus polymerase: implications for biochemical functions and drug design. Nucl Acids Res 2003; 31: 7117–71-30.
103. Gorbalenya AE, Pringle FM, Zeddam J-L. The palm subdomain-based active site is internally permuted in viral RNA-dependent RNA polymerases of an ancient lineage. J Mol Biol 2002; 324: 47–62.
104. Cheng A, Zhang W, Xie Y. Expression, purification, and characterization of SARS coronavirus RNA polymerase. Virology 2005; 335: 165–1-76.
105. Ma Y, Wu L, Shaw N. Structural basis and functional analysis of the SARS coronavirus nsp14–nsp10 complex. Proc Natl Acad Sci 2015; 112: 9436–94-41.
106. Witkowski JT, Robins RK, Sidwell RW. Design, synthesis, and broad spectrum antiviral activity of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide and related nucleosides. J Med Chem 1972; 15: 1150–115-4.
107. Sidwell RW, Huffman JH, Khare GP. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972; 177: 705–70-6.
108. Wilson SZ, Knight V, Wyde PR. Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob Agents Chemother 1980; 17: 642–64-8.
109. Wyde PR, Wilson SZ, Gilbert BE. Protection of mice from lethal influenza virus infection with high dose-short duration ribavirin aerosol. Antimicrob Agents Chemother 1986; 30: 942–94-4.
110. Snell NJ., Ribavirin–current status of a broad spectrum antiviral agent. Expert Opin Pharmacother 2001; 2: 1317–13-24.
111. Lau JY, Tam RC, Liang TJ. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35: 1002–100-9.
112. Crotty S, Maag D, Arnold JJ. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med 2000; 6: 1375–137-9.
113. Benzaria S, Bardiot D, Bouisset T. 2'-C-Methyl branched pyrimidine ribonucleoside analogues: potent inhibitors of RNA virus replication. Antiviral Chem Chemother 2007; 18: 225–242.
114. Carroll SS, Tomassini JE, Bosserman M. Inhibition of hepatitis C virus RNA replication by 2'-modified nucleoside analogs. J Biol Chem 2003; 278: 11979–119-84.
115. Eldrup AB, Prhavc M, Brooks J. Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication. J Med Chem 2004; 47: 5284–52-97.
116. Julander JG, Jha AK, Choi JA. Efficacy of 2'-C-methylcytidine against yellow fever virus in cell culture and in a hamster model. Antiviral Res 2010; 86: 261–26-7.
117. Olsen DB, Eldrup AB, Bartholomew L. A 7-deaza-adenosine analog is a potent and selective inhibitor of hepatitis C virus replication with excellent pharmacokinetic properties. Antimicrob Agents Chemother 2004; 48: 3944–39-53.
118. Schul W, Liu W, Xu HY. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 2007; 195: 665–6-74.
119. Pierra C, Amador A, Benzaria S. Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C-methylcytidine. J Med Chem 2006; 49: 6614–66-20.
120. Carroll SS, Ludmerer S, Handt L. Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees. Antimicrob Agents Chemother 2009; 53: 926–9-34.
121. Mello C, Aguayo E, Rodriguez M. Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C. Antimicrob Agents Chemother 2014; 58: 1546–15-55.
122. Yin Z, Chen YL, Schul W. An adenosine nucleoside inhibitor of dengue virus. Proc Natl Acad Sci USA 2009; 106: 20435–2043-9.
123. Latour DR, Jekle A, Javanbakht H. Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-D-2'-ethynyl-7-deaza-adenosine triphosphate. Antiviral Res 2010; 87: 213–2-22.
124. Shang L, Wang Y, Qing J. An adenosine nucleoside analogue NITD008 inhibits EV71 proliferation. Antiviral Res 2014; 112: 47–58.
125. Deng CL, Yeo H, Ye HQ. Inhibition of enterovirus 71 by adenosine analog NITD008. J Virol 2014; 88: 11915–119-23.
126. Meng WD, andQing FL., Fluorinated nucleosides as antiviral and antitumor agents. Curr Top Med Chem 2006; 6: 1499–1-528.
127. Tuttle JV, Tisdale M, andKrenitsky TA., Purine 2'-deoxy-2'-fluororibosides as antiinfluenza virus agents. J Med Chem 1993; 36: 119–1-25.
128. Jakeman KJ, Tisdale M, Russell S. Efficacy of 2'-deoxy-2'-fluororibosides against influenza A and B viruses in ferrets. Antimicrob Agents Chemother 1994; 38: 1864–186-7.
129. Tisdale M, Ellis M, Klumpp K. Inhibition of influenza virus transcription by 2'-deoxy-2'-fluoroguanosine. Antimicrob Agents Chemother 1995; 39: 2454–245-8.
130. Kumaki Y, Day CW, Smee DF. In vitro and in vivo efficacy of fluorodeoxycytidine analogs against highly pathogenic avian influenza H5N1, seasonal, and pandemic H1N1 virus infections. Antiviral Res 2011; 92: 329–3-40.
131. Wu JZ, Larson G, Walker H. Phosphorylation of ribavirin and viramidine by adenosine kinase and cytosolic 5'-nucleotidase II: Implications for ribavirin metabolism in erythrocytes. Antimicrob Agents Chemother 2005; 49: 2164–21-71.
132. Shi J, Du J, Ma T. Synthesis and anti-viral activity of a series of D- and L-2'-deoxy-2'-fluororibonucleosides in the subgenomic HCV replicon system. Bioorg Med Chem 2005; 13: 1641–16-52.
133. Stuyver LJ, McBrayer TR, Whitaker T. Inhibition of the subgenomic hepatitis C virus replicon in huh-7 cells by 2'-deoxy-2'-fluorocytidine. Antimicrob Agents Chemother 2004; 48: 651–65-4.
134. Fung A, Jin Z, Dyatkina N. Efficiency of incorporation and chain termination determines the inhibition potency of 2'-modified nucleotide analogs against hepatitis C virus polymerase. Antimicrob Agents Chemother 2014; 58: 3636–36-45.
135. Wohlrab F, Jamieson AT, Hay J. The effect of 2'-fluoro-2'-deoxycytidine on herpes virus growth. Biochim Biophys Acta 1985; 824: 233–2-42.
136. Richardson FC, Kuchta RD, Mazurkiewicz A. Polymerization of 2'-fluoro- and 2'-O-methyl-dNTPs by human DNA polymerase alpha, polymerase gamma, and primase. Biochem Pharmacol 2000; 59: 1045–10-52.
137. Richardson FC, Tennant BC, Meyer DJ. An evaluation of the toxicities of 2'-fluorouridine and 2'-fluorocytidine-HCl in F344 rats and woodchucks (Marmota monax). Toxicol Pathol 1999; 27: 607–6-17.
138. Furuta Y, Takahashi K, Fukuda Y. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother 2002; 46: 977–9-81.
139. Sidwell RW, Barnard DL, Day CW. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob Agents Chemother 2007; 51: 845–8-51.
140. Furuta Y, Takahashi K, Kuno-Maekawa M. Mechanism of action of T-705 against influenza virus. Antimicrob Agents Chemother 2005; 49: 981–98-6.
141. Furuta Y, Takahashi K, Shiraki K. T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections. Antiviral Res 2009; 82: 95–102.
142. Baranovich T, Wong SS, Armstrong J, et al. T-705 (Favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro. J Virol 2013; 87: 3741–3751.
143. Jin Z, Smith LK, Rajwanshi VK. The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase. PLoS One 2013; 8: e68347.
144. Oestereich L, Lüdtke A, Wurr S. Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. Antiviral Res 2014; 105: 17–21.
145. Smither SJ, Eastaugh LS, Steward JA. Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model. Antiviral Res 2014; 104: 153–15-5.
146. Gowen BB, Smee DF, Wong MH. Treatment of late stage disease in a model of arenaviral hemorrhagic fever: T-705 efficacy and reduced toxicity suggests an alternative to ribavirin. PLoS One 2008; 3: e3725.
147. Gowen BB, Wong MH, Jung KH. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob Agents Chemother 2007; 51: 3168–31-76.
148. Gowen BB, Wong MH, Jung KH. Efficacy of favipiravir (T-705) and T-1106 pyrazine derivatives in phlebovirus disease models. Antiviral Res 2010; 86: 121–12-7.
149. Julander JG, Shafer K, Smee DF. Activity of T-705 in a hamster model of yellow fever virus infection in comparison with that of a chemically related compound, T-1106. Antimicrob Agents Chemother 2009; 53: 202–20-9.
150. Julander JG, Smee DF, Morrey JD. Effect of T-705 treatment on western equine encephalitis in a mouse model. Antiviral Res 2009; 82: 169–1-71.
151. Mendenhall M, Russell A, Juelich T. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob Agents Chemother 2011; 55: 782–78-7.
152. Rocha-Pereira J, Jochmans D, Dallmeier K. Favipiravir (T-705) inhibits in vitro norovirus replication. Biochem Biophys Res Commun 2012; 424: 777–7-80.
153. de Avila AI, Gallego I, Soria ME. Lethal mutagenesis of hepatitis C virus induced by favipiravir. PLoS One 2016; 11: e0164691.
154. Jin Z, Kinkade A, Behera I. Structure-activity relationship analysis of mitochondrial toxicity caused by antiviral ribonucleoside analogs. Antiviral Res 2017; 143: 151–1-61.
155. Jin Z, Tucker K, Lin X. Biochemical evaluation of the inhibition properties of favipiravir and 2'-C-methyl-cytidine triphosphates against human and mouse norovirus RNA polymerases. Antimicrob Agents Chemother 2015; 59: 7504–75-16.
156. Huchting J, Winkler M, Nasser H. Synthesis of T-705-ribonucleoside and T-705-ribonucleotide and studies of chemical stability. ChemMedChem 2017; 12: 652–659.
157. Vanderlinden E, Vrancken B, Van Houdt J. Distinct effects of T-705 (favipiravir) and ribavirin on influenza virus replication and viral RNA synthesis. Antimicrob Agents Chemother 2016; 60: 6679–66-91.
158. Wang G, Deval J, Hong J. Discovery of 4'-chloromethyl-2'-deoxy-3',5'-di-O-isobutyryl-2'-fluorocytidine (ALS-8176), a first-in-class RSV polymerase inhibitor for treatment of human respiratory syncytial virus infection. J Med Chem 2015; 58: 1862–18-78.
159. Deval J, Hong J, Wang G. Molecular basis for the selective inhibition of respiratory syncytial virus RNA polymerase by 2'-fluoro-4'-chloromethyl-cytidine triphosphate. PLoS Pathog 2015; 11: e1004995.
160. Meng JDJ, Jekle A, andSymons J., Development of ALS-8112/ALS-8176 as an effective replication inhibitor of human metapneumovirus. In: 30th ICAR - International society for antiviral research, Atlanta, 2100–25 May 2017, Abstract 160.
161. DeVincenzo JP, McClure MW, Symons JA. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med 2015; 373: 2048–20-58.
162. Warren TK, Jordan R, Lo MK. Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. Nature 2016; 531: 381–38-5.
163. Lo MK, Jordan R, Arvey A. GS-5734 and its parent nucleoside analog inhibit filo-, pneumo-, and paramyxoviruses. Sci Reports 2017; 7: 43395.
164. Siegel D, Hui HC, Doerffler E. Discovery and synthesis of a phosphoramidate prodrug of a pyrrolo[2,1-f][triazin-4-amino] adenine C-nucleoside (GS-5734) for the treatment of Ebola and emerging viruses. J Med Chem 2017; 60: 1648–16-61.
165. Feng JY, Cheng G, Perry J. Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug. Antimicrob Agents Chemother 2014; 58: 1930–19-42.
166. Cho A, Zhang L, Xu J. Discovery of the first C-nucleoside HCV polymerase inhibitor (GS-6620) with demonstrated antiviral response in HCV infected patients. J Med Chem 2014; 57: 1812–18-25.
167. Jacobs M, Rodger A, Bell DJ. Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet 2016; 388: 498–503.
168. Dornemann J, Burzio C, Ronsse A, First newborn baby to receive experimental therapies survives Ebola virus disease. J Infect Dis 2017; 215: 171–17-4.
169. Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med 2017; 9: eaal3653.
170. Agostini MAE, Lu X, Sims A. The nucleoside prodrug GS-5734 inhibits multiple coronaviruses and selects for resistance mutations in the RNA-dependent RNA polymerase that are associated with a decrease in viral replication fitness. In: 30th ICAR - International society for antiviral research, Atlanta, 21–25 May 2017, Abstract 155.